{"transactions":[{"id":754852,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-02T20:48:18.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":false,"shares":2799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":2799},"source":{"system":"sec-edgar","filing":"0001683600-26-000002","document":"form4-06022026_080613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000168360026000002/form4-06022026_080613.xml","form_type":"4"}},{"id":754851,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-02T20:48:18.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":2026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026."}],"balance_after":2026,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":2026},"source":{"system":"sec-edgar","filing":"0001683600-26-000002","document":"form4-06022026_080613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000168360026000002/form4-06022026_080613.xml","form_type":"4"}},{"id":754850,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2026-06-02T20:48:18.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":12158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026."}],"balance_after":12158,"derivative":{"exercise_price":48.38,"expiration_date":"2036-05-28","underlying":"Class A Ordinary Shares","underlying_shares":12158},"source":{"system":"sec-edgar","filing":"0001683600-26-000002","document":"form4-06022026_080613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000168360026000002/form4-06022026_080613.xml","form_type":"4"}},{"id":754849,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Share","published_at":"2026-06-02T20:48:18.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":true,"shares":2799,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":15345,"source":{"system":"sec-edgar","filing":"0001683600-26-000002","document":"form4-06022026_080613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000168360026000002/form4-06022026_080613.xml","form_type":"4"}},{"id":1084054,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.57,"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084053,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":95.12,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084052,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":43.15,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084051,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084050,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":100.13,"underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084049,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":54.13,"underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084048,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29900,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":86.6,"underlying":"Common Stock","underlying_shares":29900},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084047,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":81.44,"underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084046,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":36.05,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084045,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":28.36,"underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084044,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":37092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084043,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51103,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."}],"balance_after":37092,"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1084042,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-21T23:45:09.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":21353,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 259 shares that were previously acquired under the Issuer's employee stock purchase plan."}],"balance_after":88195,"source":{"system":"sec-edgar","filing":"0001104659-25-069381","document":"tm2521348-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000110465925069381/tm2521348-14_4seq1.xml","form_type":"4"}},{"id":1121407,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-06-05T20:59:33.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":false,"shares":3173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":3173},"source":{"system":"sec-edgar","filing":"0001415889-25-015792","document":"form4-06052025_080654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588925015792/form4-06052025_080654.xml","form_type":"4"}},{"id":1121406,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-06-05T20:59:33.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":2799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025."}],"balance_after":2799,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":2799},"source":{"system":"sec-edgar","filing":"0001415889-25-015792","document":"form4-06052025_080654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588925015792/form4-06052025_080654.xml","form_type":"4"}},{"id":1121405,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2025-06-05T20:59:33.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":16798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025."}],"balance_after":16798,"derivative":{"exercise_price":29.11,"expiration_date":"2035-06-02","underlying":"Class A Ordinary Shares","underlying_shares":16798},"source":{"system":"sec-edgar","filing":"0001415889-25-015792","document":"form4-06052025_080654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588925015792/form4-06052025_080654.xml","form_type":"4"}},{"id":1121404,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Share","published_at":"2025-06-05T20:59:33.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":true,"shares":3173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":12546,"source":{"system":"sec-edgar","filing":"0001415889-25-015792","document":"form4-06052025_080654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588925015792/form4-06052025_080654.xml","form_type":"4"}},{"id":1217425,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-07T21:12:36.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":5262,"price":88.8,"value":467265.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":66583,"source":{"system":"sec-edgar","filing":"0001415889-25-007400","document":"form4-03072025_090332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588925007400/form4-03072025_090332.xml","form_type":"4"}},{"id":1228530,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T22:20:00.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":22000,"derivative":{"exercise_price":96.57,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-006607","document":"form4-03042025_100355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588925006607/form4-03042025_100355.xml","form_type":"4"}},{"id":1228529,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-04T22:20:00.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 11,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan."}],"balance_after":71845,"source":{"system":"sec-edgar","filing":"0001415889-25-006607","document":"form4-03042025_100355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588925006607/form4-03042025_100355.xml","form_type":"4"}},{"id":1486892,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2024-06-07T20:37:53.000Z","date":"2024-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs."}],"balance_after":0,"derivative":{"underlying":"Class A Common Shares","underlying_shares":4373},"source":{"system":"sec-edgar","filing":"0001415889-24-016000","document":"form4-06072024_080650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588924016000/form4-06072024_080650.xml","form_type":"4"}},{"id":1486891,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2024-06-07T20:37:53.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":3173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024."}],"balance_after":3173,"derivative":{"underlying":"Class A Common Shares","underlying_shares":3173},"source":{"system":"sec-edgar","filing":"0001415889-24-016000","document":"form4-06072024_080650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588924016000/form4-06072024_080650.xml","form_type":"4"}},{"id":1486890,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2024-06-07T20:37:53.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":19040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024."}],"balance_after":19040,"derivative":{"exercise_price":19.71,"expiration_date":"2034-06-04","underlying":"Class A Common Shares","underlying_shares":19040},"source":{"system":"sec-edgar","filing":"0001415889-24-016000","document":"form4-06072024_080650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588924016000/form4-06072024_080650.xml","form_type":"4"}},{"id":1486889,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Share","published_at":"2024-06-07T20:37:53.000Z","date":"2024-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4373,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."}],"balance_after":9373,"source":{"system":"sec-edgar","filing":"0001415889-24-016000","document":"form4-06072024_080650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588924016000/form4-06072024_080650.xml","form_type":"4"}},{"id":1584168,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-11T22:18:16.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":5194,"price":90.69,"value":471043.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":60498,"source":{"system":"sec-edgar","filing":"0001415889-24-007551","document":"form4-03112024_100310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588924007551/form4-03112024_100310.xml","form_type":"4"}},{"id":1591736,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T21:25:53.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2024 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":25000,"derivative":{"exercise_price":95.12,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-007032","document":"form4-03062024_090333.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588924007032/form4-03062024_090333.xml","form_type":"4"}},{"id":1591735,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-06T21:25:53.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 12,500 restricted stock units under the Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":65692,"source":{"system":"sec-edgar","filing":"0001415889-24-007032","document":"form4-03062024_090333.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588924007032/form4-03062024_090333.xml","form_type":"4"}},{"id":1650386,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-12T16:39:18.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.68,"expiration_date":"2031-11-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014702","document":"tm245865-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014702/tm245865-5_4seq1.xml","form_type":"4"}},{"id":1650385,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-12T16:39:18.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":25556},"source":{"system":"sec-edgar","filing":"0001104659-24-014702","document":"tm245865-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014702/tm245865-5_4seq1.xml","form_type":"4"}},{"id":1650384,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-12T16:39:18.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001104659-24-014702","document":"tm245865-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014702/tm245865-5_4seq1.xml","form_type":"4"}},{"id":1650383,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-02-12T16:39:18.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50303,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50303},"source":{"system":"sec-edgar","filing":"0001104659-24-014702","document":"tm245865-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014702/tm245865-5_4seq1.xml","form_type":"4"}},{"id":1650382,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:39:18.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001104659-24-014702","document":"tm245865-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014702/tm245865-5_4seq1.xml","form_type":"4"}},{"id":1839769,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-07-03T20:15:16.000Z","date":"2023-06-29","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs."}],"balance_after":0,"derivative":{"underlying":"Class A Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-23-010563","document":"form4-07032023_040710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588923010563/form4-07032023_040710.xml","form_type":"4"}},{"id":1839768,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Share","published_at":"2023-07-03T20:15:16.000Z","date":"2023-06-29","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001415889-23-010563","document":"form4-07032023_040710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588923010563/form4-07032023_040710.xml","form_type":"4"}},{"id":1853418,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:49:36.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":19597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":19597,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001415889-23-009952","document":"form4-06162023_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009952/form4-06162023_080624.xml","form_type":"4"}},{"id":1853417,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-16T16:49:36.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":13090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."}],"balance_after":13090,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001415889-23-009952","document":"form4-06162023_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009952/form4-06162023_080624.xml","form_type":"4"}},{"id":1862463,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-06-08T20:19:19.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":4373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023."}],"balance_after":4373,"derivative":{"underlying":"Class A Common Shares","underlying_shares":4373},"source":{"system":"sec-edgar","filing":"0001415889-23-009421","document":"form4-06082023_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588923009421/form4-06082023_080616.xml","form_type":"4"}},{"id":1862462,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2023-06-08T20:19:19.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":26236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023."}],"balance_after":26236,"derivative":{"exercise_price":15.19,"expiration_date":"2033-06-05","underlying":"Class A Common Shares","underlying_shares":26236},"source":{"system":"sec-edgar","filing":"0001415889-23-009421","document":"form4-06082023_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588923009421/form4-06082023_080616.xml","form_type":"4"}},{"id":1963323,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2023-03-09T02:27:37.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":106,"price":44.41,"value":4707.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $43.80 to $44.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":52666,"source":{"system":"sec-edgar","filing":"0001415889-23-004558","document":"form4-03092023_020332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588923004558/form4-03092023_020332.xml","form_type":"4"}},{"id":1963322,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2023-03-09T02:27:37.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":3216,"price":45.72,"value":147035.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":52772,"source":{"system":"sec-edgar","filing":"0001415889-23-004558","document":"form4-03092023_020332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588923004558/form4-03092023_020332.xml","form_type":"4"}},{"id":1973666,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-04T01:02:39.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":25000,"derivative":{"exercise_price":43.15,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-004258","document":"form4-03042023_010329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588923004258/form4-03042023_010329.xml","form_type":"4"}},{"id":1973665,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2023-03-04T01:02:39.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":55988,"source":{"system":"sec-edgar","filing":"0001415889-23-004258","document":"form4-03042023_010329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588923004258/form4-03042023_010329.xml","form_type":"4"}},{"id":2070646,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-01-04T16:19:48.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":2772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":50303,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2772},"source":{"system":"sec-edgar","filing":"0001415889-23-000301","document":"form4-01042023_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923000301/form4-01042023_090120.xml","form_type":"4"}},{"id":2146109,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-10-04T16:15:45.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":2876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":47531,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2876},"source":{"system":"sec-edgar","filing":"0001415889-22-010222","document":"form4-10042022_011012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922010222/form4-10042022_011012.xml","form_type":"4"}},{"id":2215877,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-07-05T16:34:56.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":3055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":44655,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3055},"source":{"system":"sec-edgar","filing":"0001415889-22-007342","document":"form4-07052022_010742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922007342/form4-07052022_010742.xml","form_type":"4"}},{"id":2218740,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-06-30T20:21:06.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022."}],"balance_after":5000,"derivative":{"underlying":"Class A Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-22-007107","document":"form4-06302022_010657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588922007107/form4-06302022_010657.xml","form_type":"4"}},{"id":2218739,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2022-06-30T20:21:06.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022."}],"balance_after":30000,"derivative":{"exercise_price":9.88,"expiration_date":"2032-06-28","underlying":"Class A Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-22-007107","document":"form4-06302022_010657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000141588922007107/form4-06302022_010657.xml","form_type":"4"}},{"id":2228944,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T16:07:19.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":25556,"price":3.37,"value":86123.72,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 6,389 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":25556,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":25556},"source":{"system":"sec-edgar","filing":"0001415889-22-006699","document":"form4-06172022_010652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006699/form4-06172022_010652.xml","form_type":"4"}},{"id":2228943,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-06-17T16:07:19.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":8712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/2022, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":41600,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8712},"source":{"system":"sec-edgar","filing":"0001415889-22-006699","document":"form4-06172022_010652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006699/form4-06172022_010652.xml","form_type":"4"}},{"id":2309839,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-04-04T16:13:25.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":2888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":32888,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2888},"source":{"system":"sec-edgar","filing":"0001179110-22-002537","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022002537/edgar.xml","form_type":"4"}},{"id":2344486,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-08T21:05:43.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":1047,"price":56.19,"value":58830.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.18 to $57.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":43227,"source":{"system":"sec-edgar","filing":"0001415889-22-002736","document":"form4-03082022_040325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588922002736/form4-03082022_040325.xml","form_type":"4"}},{"id":2344485,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-08T21:05:43.000Z","date":"2022-03-03","kind":"sale","acquired":false,"shares":1667,"price":60.28,"value":100486.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person"}],"balance_after":44274,"source":{"system":"sec-edgar","filing":"0001415889-22-002736","document":"form4-03082022_040325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588922002736/form4-03082022_040325.xml","form_type":"4"}},{"id":2354552,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T01:02:37.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":25000,"derivative":{"exercise_price":61.31,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-22-002437","document":"form4-03032022_050323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588922002437/form4-03032022_050323.xml","form_type":"4"}},{"id":2354551,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-04T01:02:37.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":45941,"source":{"system":"sec-edgar","filing":"0001415889-22-002437","document":"form4-03032022_050323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000141588922002437/form4-03032022_050323.xml","form_type":"4"}},{"id":2478958,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-09T21:01:49.000Z","date":"2021-12-07","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on October 3, 2016 and fully vested as of the date hereof."}],"balance_after":55000,"derivative":{"exercise_price":28.36,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-010721","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021010721/edgar.xml","form_type":"4"}},{"id":2478957,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:01:49.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":100,"price":95.54,"value":9554.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":33441,"source":{"system":"sec-edgar","filing":"0001179110-21-010721","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021010721/edgar.xml","form_type":"4"}},{"id":2478956,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:01:49.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":572,"price":96.38,"value":55129.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.87 to $96.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":33541,"source":{"system":"sec-edgar","filing":"0001179110-21-010721","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021010721/edgar.xml","form_type":"4"}},{"id":2478955,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:01:49.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":4328,"price":97.46,"value":421806.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.97 to $97.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":34113,"source":{"system":"sec-edgar","filing":"0001179110-21-010721","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021010721/edgar.xml","form_type":"4"}},{"id":2478954,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:01:49.000Z","date":"2021-12-07","kind":"exercise","acquired":true,"shares":5000,"price":28.36,"value":141800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 167 shares that were previously acquired under the Issuer's employee stock purchase plan."}],"balance_after":38441,"source":{"system":"sec-edgar","filing":"0001179110-21-010721","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021010721/edgar.xml","form_type":"4"}},{"id":2509131,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-17T16:10:05.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":44000,"price":5.68,"value":249920.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":5.68,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001179110-21-010213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021010213/edgar.xml","form_type":"4"}},{"id":2509130,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-11-17T16:10:05.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-010213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021010213/edgar.xml","form_type":"4"}},{"id":2522927,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:01:43.000Z","date":"2021-11-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on October 3, 2016 and fully vested as of the date hereof."}],"balance_after":60000,"derivative":{"exercise_price":28.36,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-009894","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021009894/edgar.xml","form_type":"4"}},{"id":2522926,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-05T20:01:43.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":800,"price":109.63,"value":87704.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.39 to $109.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":33274,"source":{"system":"sec-edgar","filing":"0001179110-21-009894","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021009894/edgar.xml","form_type":"4"}},{"id":2522925,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-05T20:01:43.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":4200,"price":110.74,"value":465108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.23 to $111.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":34074,"source":{"system":"sec-edgar","filing":"0001179110-21-009894","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021009894/edgar.xml","form_type":"4"}},{"id":2522924,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-05T20:01:43.000Z","date":"2021-11-03","kind":"exercise","acquired":true,"shares":5000,"price":28.36,"value":141800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":38274,"source":{"system":"sec-edgar","filing":"0001179110-21-009894","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021009894/edgar.xml","form_type":"4"}},{"id":2558863,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-27T20:30:23.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on October 3, 2016 and fully vested as of the date hereof."}],"balance_after":65000,"derivative":{"exercise_price":28.36,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-21-008943","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021008943/edgar.xml","form_type":"4"}},{"id":2558862,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-27T20:30:23.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":2921,"price":107.75,"value":314737.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.74 to $108.08 per share."}],"balance_after":33274,"source":{"system":"sec-edgar","filing":"0001179110-21-008943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021008943/edgar.xml","form_type":"4"}},{"id":2558861,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-27T20:30:23.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":17317,"price":108.78,"value":1883743.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.18 to $109.08 per share."}],"balance_after":36195,"source":{"system":"sec-edgar","filing":"0001179110-21-008943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021008943/edgar.xml","form_type":"4"}},{"id":2558860,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-27T20:30:23.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":4762,"price":109.8,"value":522867.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 to $110.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) in this form 4."}],"balance_after":53512,"source":{"system":"sec-edgar","filing":"0001179110-21-008943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021008943/edgar.xml","form_type":"4"}},{"id":2558859,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-27T20:30:23.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":25000,"price":28.36,"value":709000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted  on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 422 shares that were previously acquired under the Issuer's employee stock purchase plan."}],"balance_after":58274,"source":{"system":"sec-edgar","filing":"0001179110-21-008943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021008943/edgar.xml","form_type":"4"}},{"id":2650184,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2021-06-30T20:22:20.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":33237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021."}],"balance_after":33237,"derivative":{"exercise_price":14.33,"expiration_date":"2031-06-28","underlying":"Class A Common Shares","underlying_shares":33237},"source":{"system":"sec-edgar","filing":"0001179110-21-007186","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021007186/edgar.xml","form_type":"4"}},{"id":2806322,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:50:16.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":1772,"price":86.61,"value":153472.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":32852,"source":{"system":"sec-edgar","filing":"0001179110-21-003009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021003009/edgar.xml","form_type":"4"}},{"id":2806321,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:50:16.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":121,"price":89,"value":10769.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.99 to $89.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34624,"source":{"system":"sec-edgar","filing":"0001179110-21-003009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021003009/edgar.xml","form_type":"4"}},{"id":2813793,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T21:26:08.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":26125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":26125,"derivative":{"exercise_price":100.13,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001179110-21-002666","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021002666/edgar.xml","form_type":"4"}},{"id":2813792,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:26:08.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":13062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":34745,"source":{"system":"sec-edgar","filing":"0001179110-21-002666","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911021002666/edgar.xml","form_type":"4"}},{"id":3092284,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2020-07-02T20:11:11.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":18760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020."}],"balance_after":18760,"derivative":{"exercise_price":25.48,"expiration_date":"2030-06-29","underlying":"Class A Common Shares","underlying_shares":18760},"source":{"system":"sec-edgar","filing":"0001104659-20-080547","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465920080547/a4.xml","form_type":"4"}},{"id":3215890,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-11T20:28:56.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":617,"price":51.98,"value":32071.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":21683,"source":{"system":"sec-edgar","filing":"0001179110-20-003470","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911020003470/edgar.xml","form_type":"4"}},{"id":3232706,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T00:10:13.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":28500,"derivative":{"exercise_price":54.13,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001179110-20-002961","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911020002961/edgar.xml","form_type":"4"}},{"id":3232705,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-04T00:10:13.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 14,250 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 14,250 newly awarded restricted stock units, and 8,050 previously reported restricted stock units, 2,013 of which vested on March 1, 2020."}],"balance_after":22300,"source":{"system":"sec-edgar","filing":"0001179110-20-002961","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911020002961/edgar.xml","form_type":"4"}},{"id":3507641,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option","published_at":"2019-05-30T22:32:31.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":18760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019."}],"balance_after":18760,"derivative":{"exercise_price":15.47,"expiration_date":"2029-05-28","underlying":"Class A Common Shares","underlying_shares":18760},"source":{"system":"sec-edgar","filing":"0001179110-19-006867","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911019006867/edgar.xml","form_type":"4"}},{"id":3612903,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-03-05T22:25:21.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":8050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023."}],"balance_after":8050,"derivative":{"underlying":"Common Stock","underlying_shares":8050},"source":{"system":"sec-edgar","filing":"0001179110-19-003308","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911019003308/edgar.xml","form_type":"4"}},{"id":3612902,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-05T22:25:21.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":29900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":29900,"derivative":{"exercise_price":86.6,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":29900},"source":{"system":"sec-edgar","filing":"0001179110-19-003308","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911019003308/edgar.xml","form_type":"4"}},{"id":4024044,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-01T22:08:38.000Z","date":"2018-02-27","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on October 3, 2016. This option vested with respect to 25% of the shares underlying the option on September 6, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":134000,"derivative":{"exercise_price":28.36,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-18-003163","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018003163/edgar.xml","form_type":"4"}},{"id":4024043,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-03-01T22:08:38.000Z","date":"2018-02-27","kind":"sale","acquired":false,"shares":1106,"price":87.69,"value":96985.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.47 to $87.85 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-18-003163","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018003163/edgar.xml","form_type":"4"}},{"id":4024042,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-03-01T22:08:38.000Z","date":"2018-02-27","kind":"sale","acquired":false,"shares":8794,"price":88.4,"value":777389.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.90 to $88.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":1106,"source":{"system":"sec-edgar","filing":"0001179110-18-003163","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018003163/edgar.xml","form_type":"4"}},{"id":4024041,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-03-01T22:08:38.000Z","date":"2018-02-27","kind":"sale","acquired":false,"shares":100,"price":90.75,"value":9075.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act."}],"balance_after":9900,"source":{"system":"sec-edgar","filing":"0001179110-18-003163","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018003163/edgar.xml","form_type":"4"}},{"id":4024040,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-03-01T22:08:38.000Z","date":"2018-02-27","kind":"exercise","acquired":true,"shares":10000,"price":28.36,"value":283600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001179110-18-003163","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018003163/edgar.xml","form_type":"4"}},{"id":4047944,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-20T22:33:00.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":144000,"derivative":{"exercise_price":81.44,"expiration_date":"2028-02-16","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001179110-18-002415","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911018002415/edgar.xml","form_type":"4"}},{"id":4436334,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-21T21:42:00.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":105000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-17-002770","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911017002770/edgar.xml","form_type":"4"}},{"id":4587166,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":42414,"kind":"person","name":"McCain Tracey L","position":1,"cik":"0001683600","reported_name":"McCain Tracey L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-04T22:22:44.000Z","date":"2016-10-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"In accordance with the Issuer's equity award grant policy, this option was granted effective as of the first day of the month following the commencement of the Reporting Person's employment with the Issuer on September 6, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 25% of the shares underlying the option on September 6, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":100000,"derivative":{"exercise_price":28.36,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-16-030355","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683600/000117911016030355/edgar.xml","form_type":"4"}}]}